In the trial, a TALZENNA plus XTANDI combination regimen offered overall survival (OS) improvement in metastatic ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of ...

Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC: New York Friday, October 11, 2024, 09:00 Hrs [IST] Pf ...

Baby Boomers looking to put new money to work may wish to check out the broader basket of dividend stocks while interest ...

As part of the CURE® Educated Patient® Prostate Cancer Summit, an expert discussed the role genetic testing plays in ...

Pfizer's combination of Talzenna and Xtandi has shown a notable improvement in overall survival rates for patients with metastatic castration-resistant prostate cancer (mCRPC) in a late-stage study.

On Thursday, Starboard Value LP, a significant shareholder of Pfizer Inc. (NYSE:PFE), issued a letter to the company’s Board ...

Pfizer's drug combination improves survival in prostate cancer patients. Starboard Value pressures Pfizer over board conduct.

According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...